Q4/2023 12/31/2023 EPS -0.370 ZacksConsensus -0.460 ActVsEst 0.090 - Beat
Omega Therapeutics, Inc. (OMGA)
Company Research
Source: Wall Street Horizon
Impact Snapshot
Event Time:
OMGA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OMGA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OMGA alerts
High impacting Omega Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
OMGA
News
- Omega Therapeutics, Inc. (NASDAQ: OMGA) was downgraded by analysts at Raymond James from an "outperform" rating to a "market perform" rating.MarketBeat
- Omega Therapeutics, Inc. (NASDAQ: OMGA) had its price target lowered by analysts at Piper Sandler from $9.00 to $4.00. They now have an "overweight" rating on the stock.MarketBeat
- Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial ResultsGlobeNewswire
- Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific MeetingsGlobeNewswire
- Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature CommunicationsGlobeNewswire
OMGA
Earnings
- 11/14/24 - Miss
OMGA
Sec Filings
- 11/15/24 - Form 4
- 11/14/24 - Form 8-K
- 11/14/24 - Form 10-Q
- OMGA's page on the SEC website